Stockscreener 앱 받기
17.61
3.98%
-0.73
시간 외 거래:
17.60
-0.010
-0.06%
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Denali Therapeutics Inc. (DNLI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Zacks Investment Research
Alector, Inc. (ALEC) Stock Price, News, Quote & History - Yahoo Finance
Denali Therapeutics (NasdaqGS:DNLI) Stock Forecast & Analyst Predictions - Simply Wall Street
Denali Therapeutics (DNLI) Stock Looks Stretched On Fair Value Yet Reasonable On Book Value - simplywall.st
The Technical Signals Behind (DNLI) That Institutions Follow - Stock Traders Daily
Denali at Cantor global healthcare conference: launch gains traction By Investing.com - Investing.com India
Denali at Cantor global healthcare conference: launch gains traction By Investing.com - Investing.com UK
Denali Therapeutics (DNLI) Institutional Ownership 2026 $DNLI - MarketBeat
Denali Therapeutics Insider Transactions: Officer Peter Scott Chin to Sell 1,654 Shares, Director Nancy Thornberry Sells 11,439 Shares (NASDAQ: DNLI) - kalkinemedia.com
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com UK
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com South Africa
Denali Therapeutics director sells $261,928 in stock - Investing.com
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com Canada
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com Nigeria
Denali Therapeutics director sells $261,928 in stock - Investing.com
Denali Therapeutics (NASDAQ: DNLI) holder to sell shares to cover tax on stock units - Stock Titan
Denali Therapeutics Director Nancy Thornberry Executes Two Stock Sales Under Rule 10b5-1 Plan - kalkinemedia.com
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing - marketscreener.com
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing - Yahoo Finance
Director Nancy Thornberry plans Denali (NASDAQ: DNLI) stock sale - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) exec plans 2,768-share Rule 144 sale - stocktitan.net
Denali (DNLI) Session: Finishes 2.89% Lower at $24.20; Technical View: Price Remains Between $22.99 Support and $25.41 ResistanceOBV Trend Line - vinanet.vn
Denali Therapeutics (DNLI) Stock Dropped, So Why Is It Drawing Fresh Attention? - sahmcapital.com
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - AOL.com
145,045 Shares in Denali Therapeutics Inc. $DNLI Purchased by Great Lakes Advisors LLC - MarketBeat
Denali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term Upside - TipRanks
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? - TradingView
Edmond DE Rothschild Holding S.A. Invests $4.25 Million in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali (DNLI) Financial Update: The Available Earnings Metric Delivers a Miss for This Review; Market Reaction: Shares Finish 3.25% UpDividend Increase Stocks - vinanet.vn
Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI) - Seeking Alpha
Bank of America Corp DE Boosts Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report - Sahm
SCS Capital Management LLC Takes Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund - Kalkine Media
Denali Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DNLI | US24823R1059 - marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock - MarketBeat
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - The Globe and Mail
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One (NASDAQ:DNLI) - Seeking Alpha
Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Shows Perfect Technical Setup for a Breakout - ChartMill
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Equities Analysts Set Expectations for DNLI Q3 Earnings - MarketBeat
E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) holder to sell 2,857 restricted shares via broker - Stock Titan
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June R - GuruFocus
Weekly Recap: Q2 revenue, big net loss and DNL126 Phase 3 with 2027 BLA - TradingView
Denali climbs past Avlayah expectations with $3.6M in revenue - BioSpace
(DNLI) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The Manufacturers Life Insurance Company Lowers Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
9.65%
자본화:
|
볼륨(24시간):